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ABSTRACT
Starting with mRNA derived from Staphylococcal enterotoxin A induced
human splenocytes, dsDNA-was synthesized and inserted into the unique
BamHI site of the eukaryotic expression vector pSV529 (1). A recombinant
pITsmid containing human immune interferon (IFN-Y) cDNA was identified by
hybridization of plasmid inserted DNA bound onto nitrocellulose filters
with mRNA derived from SEA-induced splenocytes, translation of the eluted
RNA in Xenopus laevis oocytes and assaying for IFN activity. Plasmids
containing the entire human IFN-Y cONA sequence were identified by
colony hybridization and were sequenced. A unique coding region was
identified which predicted a protein of 166 amino acids, the 20
N-terminal amino acids of which presumably represent a signal peptide.
After transfection of monkey cells with plasmid DNA isolated from one of
the recombinant clones (pHIIF-SV-*8l), IFN was excreted into the culture
medium. This IFN was not distinguishable from human IFN41 by serological
criteria or by cell target species specificity.
INTRODUCTION
Immune interferon (IFN-Y) can be induced in lymphocytes by mitogens
(2), alloantigens (3) and other substances (4-7) as well as being induced
in sensitized lymphocytes by specific antigens (8). Its production is
dependent upon the presence either of macrophages or the macrophage
product interleukin 1 (ILl) and this production is regulated by
T-lymphocyte derived interleukin 2 (IL2) (9). Biologically, immune
interferon is a very interesting lymphokine with important
immunoregulatory properties (10). Reduced IFN4Y production seems to
occur in certain immunodeficiencies (11) and IFN-1 has been found in the
circulation of patients suffering from autoimmune diseases (12). It has
been shown that IFN- has a more potent anticellular activity (13, 14)
and can activate natural killer cells to a higher extent (15) than
other human IFNs. The antiviral effect (16) and the antitumour effect
(17) of virus-induced IFNs (IFN-G and IFN-L ) can be potentiated by
IFN-Y . The antiviral and antigrowth response of IFN-) on cells
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selected for their resistance towards fibroblast IFN (18) and the
differential antiviral activity of IFN-L (19) points towards a different
mechanism of action. Further important functional differences between
the type I IFNs (IFN-.Cs, IFN-,S) and type II IFN (IFN-Y) include their
different affinities for gangliosides (20) and their different membrane
receptors (21).
IFN-LV is produced by stimulated lymphocytes in minute quantities
together with numerous other lymphokines. Only recently has extensive
purification of IFN-t been achieved (22) and this has allowed a more
precise determination of the molecular size (23). The mRNA for IFN-'T
isolated from human peripheral blood lymphocyte (PBL) cultures has been
partially enriched and translated in Xenopus laevis oocytes (24-27).
Recently, we reported the characterization of IFN-r mRNA derived from
SEA-induced human splenocytes (28). We chose to use human spleen for the
isolation of IFN-V mRNA because it is a source of appreciable and
reproducible amounts of this mRNA, needed for the synthesis and
identification of a cloned cDNA copy. In this report we describe the
construction and identification of recombinant plasmids containing human
IFN-V cDNA sequences, and the synthesis of human IFN-b by cultured monkey
cells after transfection with the recombinant DNA in which the human
IFN-T cDNA is under the control of SV40 late transcription. The results
of similar work, i.e. on cloning, characterization and expression of
IFN-Y cDNA derived from human PBLs have recently been published by Gray
et al. (29).
MATERIALS AND METHODS
Construction of cDNA plasmids
Poly eRNA was prepared from SEA-induced splenocyte cultures,
purified by sucrose gradient centrifugation, and the IFN-G mRNA was
identified by injecting aliquots into Xenopus laevis oocytes and after
incubation for 72 hr assaying the incubation medium for IFN activity as
described (28). The peak of IFN-Y mRNA activity sedimented at around
13 S. cDNA was synthesized on 40
_g poly AtRNA (from a single donor,
spleen 7; ref 28) using oligo(dT),%,& (P-L Biochemicals) as a primer,
followed by second strand synthesis, SI-treatment and sizing on a 4%
polyacrylamide gel essentially as described (30). Molecules of dsDNA
ranging in length between 800 and 1000 bp (g4), 1000 and 1250 bp (g3) and
1250 and 1400 bp (g2) were eluted from the gel, purified on
hydroxyapatite and tailed with oligo dC. pSV529 DNA was used a a vector;
it contains 1.4 genome equivalents of SV40 cloned between the EcoRI site
and the PvuII site of pBR322 except that the VPl gene has been deleted
and replaced by a single BamHI site. This vector was cleaved with BamHI,
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incubated with AMV reverse transcriptase in the presence of all four
dNTPs to fill in the BamHI sticky ends, and tailed with oligo dG. After
annealing, the mixture was used to transform E. coli strain DHl (obtained
from Dr. D. Hanahan through Dr. B. Hohn). Transformants grown on LB-agar
plates containing 100 4g/ml carbenicillin were picked up and grown
overnight in microtiter plates. Dimethylsulfoxide was added to a final
concentration of 10% and the plates were stored at -70°C.
DNA preparation and screening of the cDNA library
Fifty individual clones were grown overnight on a single agar plate
and the bacteria derived from these clones were suspended in 5 ml
LB-medium. 0.5 1 LB-medium was inoculated with this suspension and the
bacteria were grown overnight (without amplification of the plasmids).
Supercoiled plasmid DNA was prepared from these cultures by CsCl gradient
centrifugation (31) and taken up in 10 mM Tris-HCl pH 7.5 - 1 mM EDTA at
a concentration of 1 mg/ml. 150jug of this DNA was digested with BamHI
followed by neutral density gradient centrifugation. The peak on the
gradient which corresponded to excised "insert DNA" was collected,
precipitated with ethanol, taken up in 10 mM Tris HCI pH 7.5 - 1 mM EDTA
and used for binding on nitrocellulose filters (7 mm $, millipore HAWP
0.45y.). The conditions for the binding of insert DNA, hybridization of
the filters with SEA-induced splenocyte poly A+RNA and elution of the RNA
were essentially as described by Parnes et al. (32), except that the RNA
was eluted in the presence of 4yg poly A RNA (oligo(dT) cellulose
runthrough RNA), and immediately precipitated without phenolization.
After centrifugation, the eluted mRNA was taken up in 2jd sterile HI0,
injected (in duplo) into each of 15-20 Xenopus laevis oocytes, and after
three days at 23 C the medium was assayed for IFN activity. Colony
hybridization was as described (33, 34).
Restriction enzyme analysis and DNA sequence determination
Plasmid DNA and sucrose gradient purified insert DNA were cleaved by
restriction endonucleases (New England Biolabs, Boehringer-Mannheim)
following the instructions of the supplier. Nucleotide sequences were
determined by the chemical degradation method of Maxam and Gilbert (35)
using 5'-end and 3'-end labelled DNA fragments.
DNA transfection of monkey cells and assay for IFN activity
Kidney cells of the African Green monkey (AP8 cells) were transfected
with recombinant SV40-plasmid DNA using a modification of the
DEAE-dextran method (36) as described by Gheysen and Fiers (1). After
24 hr and 72 hr, aliquots of the incubation medium were withdrawn and
stored at -70°C until they were assayed for IFN activity. Assay and
neutralization of IFN activity were performed as previously described (1,
28, 37).
2489
Nucleic Acids Research
RESULTS AND DISCUSSION
cDNA cloning
Recently, a eukaryotic expression vector (pSV529) designed to express
a gene under late SV40 transcriptional control was constructed and
successfully used for the expression of substantial quantities of lFN-,g
(1). These experiments suggested that this vector could also be used as
a direct screening vector for cloning eukaryotic genes corresponding to
other proteins for which a sensitive assay is available, such as that for
IFN-T. Such a screening method requires that the cDNA copy of the gene
to be expressed is full length and is inserted in the correct orientation
relative to the SV40 late promoter. If the length of the mRNA of the
gene being studied is known, full length cDNA copies can be selected and
this increases the chance of finding a biologically active clone. Since
we had previously shown (28), that the mRNA coding for IFN4 has a length
of between 900 and 1400 nucleotides, we chose to use this size range of
cDNA to construct recombinant clones. mRNA was isolated from SEA-induced
human splenocyte cultures, and purified by non-denaturing sucrose
gradient centrifugation. dsDNA was fractionated by polyacrylamide gel
electrophoresis and appropriate size classes were inserted into the
unique BamHI site of pSV529 DNA and used for transformation of E. coli
DH1. DNA was prepared from mixtures of 50 individual clones and used to
transfect AP8 monkey cells. After incubation for 48 hr and 72 hr,
aliquots of the medium were removed and assayed for IFN activity.
Screening of approximately 8000 clones by this method did not enable
us to obtain any group of 50 clones which showed reproducible IFN
activity (data not shown). We concluded that either the IFN4' was
expressed at a level below the detection limit of our assay, or that
there was no clone present in the cDNA library which contained a complete
IFN-Y cDNA copy inserted in the same orientation relative to
transcription (see below).
Although the mRNA from which the recombinant plasmids were obtained
was only purified 10-30 times after a single sucrose gradient step,
relatively high titers of IFN4 were obtained after injection into
Xenopus laevis oocytes (28). Furthermore, since we had found the human
spleen to be a reliable source of appreciable amounts of IFN4Y mRNA (28),
we believed that a positive screening of the clones by cDNA-mRNA
hybridization followed by translation in oocytes (32, 37) could be
successful. Such a screening method could be rendered more sensitive by
binding only "insert DNA" onto nitrocellulose filters, instead of binding
total recombinant plasmid DNA. Since the BamHI site of the vector pSV529
was restored by the procedure used, "insert DNA" could be prepared by
BamHI digestion of DNA from mixtures of 50 individual clones. This DNA
was purified by sucrose gradient centrifugation (Fig. 1), and bound onto
2490
Nucleic Acids Research
g3 clones Barn Hl
sucrose gradient centrifugation
RNA insert pSV529-BarnHIDNA vector
n . . .
104/I~~~~~~~~~~.
4
n it rocelIulose
filt ers
Fig. 1 Purification of BamHI excised "insert DNA" derived from mixtures
of 50 g3 clones by sucrose gradient centrifugation as outlined in
Materials and Methods. Aliquots were analysed on 4% polyacrylamide gels
before (left) and after (right) centrifugation. Isolated "insert DNA"
was ethanol precipitated and bound on nitrocellulose filters.
nitrocellulose filters. The hybridization-elution-translation assay of
20 filters each containing "insert DNA" derived from 50 g3 clones with
SEA-induced splenocyte mRNA (purified by sucrose gradient centrifugation)
yielded three groups (1, 2 and 15) which gave a clear positive signal
(see Table 1). Subsequent hybridization of filters containing "insert
DNA" derived from subgroups (each containing 8 to 9 clones) of group 2
yielded one subgroup (2-6) which showed a positive signal. The subgroup
2-6 consisted of eight clones of which only five contained an insert
which could be cut out with BamHI. Moreover, restriction enzyme analysis
(not shown) revealed three of the five clones (2-6.2, 2-6.3 and 2-6.7) to
be identical (undoubtedly they had been picked from the same
transformant). Finally, after hybridization with filters containing
individual "insert DNAs" only the clones 2-6.2, 2-6.3 and 2-6.7 gave a
strong, reproducible signal. As the three were identical, one of them
was chosen for further use and was designated as pHIIF-SV-40.
Colony hybridization of 2300 g3 colonies and 880 g2 colonies with a
V2P-labeled internal DdeI fragment (620 bp) derived from pHIIF-SV-I0
resulted in the identification of seven positive clones (pHIIF-SV-rl, 2,
2491
Nucleic Acids Research
Table 1 Identification of an IFN-Y cDNA clone
g3 groups 34 5 6 7 8 9 10 11 12 13 14 16 17 18 19 20
(50 clones each)
subgroups 21 22 23 24 25
(8 to 9 clones)
Individual clones 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8
Individual clones contain- - 26.2 26.3 26.4 - - 26.7 26.8
ing an insert that can 2.
be cut out with BamHI
Individual clones 26.4 26.8
containing a unique
insert
Circled numbers indicate filters which showed a positive signal in the
hybridization-elution translation assay.
3, 5, 6, 8, 9) in the g3 group (1 in 300) and one positive clone
(pHIIF-SV-410) in the g2 group (1 in 900). All but one of these clones
(pHIIF-SV-49) contained inserts which could be cut out with BamHI. The
size of the "insert DNA" ranged from 1000 to 1250 bp. Such a difference
in the frequency with which positive clones were found in the g3 and g2
clones was not unexpected since it is a reflection of the number of full
length cDNA copies in each group. Both group 1 and group 15 of the g3
clones which gave a positive signal in the first hybridization-elution
translation screening assay turned out to contain a positive clone.
The BamHI excised "insert" DNA derived from the pHIIF-SV-4 clones was
purified by a sucrose gradient centrifugation and analysed by digestion
with the restriction enzymes OdeI and HinfI. From the pattern obtained
after gel electrophoresis (data not shown), we were able to deduce that
there had not been any major rearrangements such as occurred during the
cloning of IFN-/S cDNA (37, 38). It was also clear that most of the DNA
preparations were heterogenous mixtures of molecules due to variation in
the length of the dG:dC tails. Such a heterogeneity may result from
slippage during replication of the plasmids.
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DNA sequence analysis
The complete nucleotide sequence of the cDNA insert of pHIIF-SV-40
and most of pHIIF-SV-4l was determined by the chemical degradation method
of maxam and Gilbert (34). The sequences of the ends of the insert cDNA
of pHIIF-SV-15 and pHIIF-SV-110 were also determined and extended the
length of the known DNA sequence. Fig. 2 shows the strategy for the
sequence analysis together with the deduced and the experimentally
verified restriction sites. The results obtained from the series of
pHIIF-SV-'1 clones enabled us to establish the primary structure of most
of the human IFN-Y mRNA as presented in Fig. 3 in the form of a double
stranded DNA sequence. A continuous reading frame of 498 nucleotides is
present starting with the first AUG (at position 92) near the 5'-end of
the mRNA and ending with a stop codon UAA (at position 590). This
continuous reading frame together with the hexanucleotide AAUAAA found in
the clone pHIIF-SV-110 before the site of polyadenylation (39) enabled us
to determine the orientation of the coding strand in the pHIIF-SV-4
clones. It may be noted that all clones analysed lacked an
oligo dA:oligo dT sequence at their 3'-end; it was presumably removed by
SI-nuclease during the synthesis of ds-cDNA. The use of the first AUG as
an initiator codon is a property common to most eukaryotic mRNAs (40).
The 3'-untranslated region is 600 nucleotides long and thus accounts for
almost half the nucleotide sequence of the mRNA; although remarkably
long, this is certainly not a unique example (41).
The amino acid sequence of human IFN4V deduced from the nucleotide
sequence of the coding region, is presented in Fig. 4. The 20
NH,-terminal amino acids of this sequence presumably comprise a signal
peptide which is removed upon secretion. Indeed, as is commonly observed
for secretory proteins (42), this sequence contains mainly hydrophobic
amino acid residues and residues 18-21, Ser-Leu-Gly-Cys, are also found
in a similar position in human IFN-4, (43), (and other IFN-4.s (44)) and,
by analogy, one might suppose that cleavage of the IFN-T signal peptide
occurs also between the glycine and cysteine residues. The deduced
protein sequence points to a mature human IFN4" that contains 146 amino
acids, and which has a calculated molecular weight of 17 147. It has
been shown that under denaturing conditions, IFN-r can give rise to two
subspecies of 20 000 dalton and 25 000 dalton but their possible
relationship is not clear (23, 45). Considering the glycosylation of
natural IFN-T (46), these estimates are in reasonable agreement with the
value deduced from the gene sequence. However, authentic IFN4V secreted
by lymphocytes has a molecular weight of approximately 45 000 dalton (47,
48, and our own unpublished observations). Even allowing for
glycosylation, this value is hard to reconcile with the molecular weight
of the polypeptide, and therefore it seems likely that the mature
2493
Nucleic Acids Research
I
- -r Ct
MD= 2_ -Wm Cam a cr
sI>m (A{OCc DC: 0a1_nu a4<ztm u-mczl 2C 0(n
4-' 4
7aL I 0
o) 4-
(a>0rZ s
)In 04- 0)O
V C04-) (0o E
_ 0 o 0)
) 0)= L4-'
C)~ ~ Cs
OM r- Ca
(L 4) Q) 8
.(A0C) 4-0 0
4J Cn 0 0 to
4- n 03
(A 0 to S-
G)4n In 4--n
04-)
o - - 4- 4-)
I a)4 0 0 i
CY 0l S-0r-
-1 0 a) 0)0-) 4-' 0)04-'
44--C I
CtCn O._ ->,
04 n 4-
8 C) -0 S- 4
4~- -r -EO
01 0)CYI 0
4L. (L)- 4-)
S- s- 4- > z
o-4 04' 0 4
a)E 0-.
m 0 n .OEmn
>jS-0)t () L.(C a)
0- 4-) 0) >.
8 <: +' o4-(A) -0rLA -r4 D0(C0 (0
Cqq000
4-0)0E 0)0-.-C
zer-: OC 0 *_4-
-J cIn 0) 4-0
(A4In-.-
eD E D *- '-Dt
0 V n L. 0.-
E C 0) CZ E.-
D (M -a a >, = aD
s S- 4- -C a0-O X
8 4-w@L -.>0 ,
0CS IS4) ) SJ
CO0 -050)(-4-Z 4- -0)
0 a) Into I
8 0) C~~~( > In0rC aO0 0)
s0 C -r- cr
CO4= ( 4-) a)
E (A In>r-40CA
0 0) 0) Ct00 -0)
(D00--0 0)~
0m *- CL @a
.r S Wu_ >I-r
0 *Inmm=
4E)OE S..o r 4)00 In a (ACOI
4r -'OO) - 4-
0 w >@S-(OLO -
4-' Q. to 4) 0
C 4-J 4- 4-J
0 0L.-L)
- -0)V-r--0)4-'O.
cma) O (DO0a)
L-=OVaSw -0
U- 0-0 orr- S
I.IHWD8-
f PUIH-
IldH
113 Is-
I dsO-
I 04X
IeDH
E UIH_1
I nsV-
4 1 IEl
IH WDL-U
2494
11
1.
1.
_
Nucleic Acids Research
AAGAGAAAGATCAGTTAAGTCCTTTGGACCTGATCAGCTTGATACAAGAACTACTGATTTCAACTTCTTTGGCTT 75
TTCTCTTTCTAGTCAATTCAGGAAACCTGGACTAGTCGAACTATGTTCTTGATGACTAAAGTTGAAGAAACCGAA
AATTCTCTCGGAAACXqAATATACAAGTTATATCTTGGCTTTTCAGCTCTGCATCGTTTTGGGTTCTCTTGG 150
TTAAGAGAGCCTTTGCTACTTTATATGTTCAATATAGAACCGAAAAGTCGAGACGTAGCAAAACCCAAGAGAACC
4
CTGTTACTGCCAGGACCCATATGTAAAAGAAGCAGAAAACCTTAAGAAATATTTTAATGCAGGTCATTCAGATGT 225
GACAATGACGGTCCTGGGTATACATTTTCTTCGTCTTTTGGAATTCTTTATAAAATTACGTCCAGTAAGTCTACA
AGCGGATAATGGAACTCTTTTCTTAGGCATTTTGAAGAATTGGAAAGAGGAGAGTGACAGAAAAATAATGCAGAG 300
TCGCCTATTACCTTGAGAAAAGAATCCGTAAAACTTCTTAACCTTTCTCCTCTCACTGTCTTTTTATTACGTCTC
CCAAATTGTCTCCTTTTACTTCAAACTTTTTAAAAACTTTAAAGATGACCAGAGCATCCAAAAGAGTGTGGAGAC 375
GGTTTAACAGAGGAAAATGAAGTTTGAAAAATTTTTGAAATTTCTACTGGTCTCGTAGGTTTTCTCACACCTCTG
CATCAAGGAAGACATGAATGTCAAGTTTTTCAATAGCAACAAAAAGAAACGAGATGACTTCGAAAAGCTGACTAA 450
GTAGTTCCTTCTGTACTTACAGTTCAAAAAGTTATCGTTGTTTTTCTTTGCTCTACTGAAGCTTTTCGACTGATT
TTATTCGGTAACTGACTTGAATGTCCAACGCAAAGCAATACATGAACTCATCCAAGTGATGGCTGAACTGTCGCC 525
AATAAGCCATTGACTGAACTTACAGGTTGCGTTTCGTTATGTACTTGAGTAGGTTCACTACCGACTTGACAGCGG
AGCAGCTAAAACAGGGAAGCGAAAAAGGAGTCAGATGCTGTTTCGAGGTCGAAGAGCATCCCAEgTGGTTGTC 600
TCGTCGATTTTGTCCCTTCGCTTTTTCCTCAGTCTACGACAAAGCTCCAGCTTCTCGTAGGGTCATTACCAACAG
CTGCCTGCAATATTTGAATTTTAAATCTAAATCTATTTATTAATATTTAACATTATTTATATGGGGAATATATTT 675
GACGGACGTTATAAACTTAAAATTTAGATTTAGATAAATAATTATAAATTGTAATAAATATACCCCTTATATAAA
TTAGACTCATCAATCAAATAAGTATTTATAATAGCAACTTTTGTGTAATGAAAATGAATATCTATTAATATATGT 750
AATCTGAGTAGTTAGTTTATTCATAAATATTATCGTTGAAAACACATTACTTTTACTTATAGATAATTATATACA
ATTATTTATAATTCCTATATCCTGTGACTGTCTCACTTAATCCTTTGTTTTCTGACTAATTAGGCAAGGCTATGT 825
TAATAAATATTAAGGATATAGGACACTGACAGAGTGAATTAGGAAACAAAAGACTGATTAATCCGTTCCGATACA
GATTACAAGGCTTTATCTCAGGGGCCAACTAGGCAGCCAACCTAAGCAAGATCCCATGGGTTGTGTGTTTATTTC 900
CTAATGTTCCGAAATAGAGTCCCCGGTTGATCCGTCGGTTGGATTCGTTCTAGGGTACCCAACACACAAATAAAG
ACTTGATGATACAATGAACACTTATAAGTGAAGTGATACTATCCAGTTACTGCCGGTTTGAAAATATGCCTGCAA 975
TGAACTACTATGTTACTTGTGAATATTCACTTCACTATGATAGGTCAATGACGGCCAAACTTTTATACGGACGTT
TCTGAGCCAGTGCTTTAATGGCATGTCAGACAGAACTTGAATGTGTCAGGTGACCCTGATGAAAACATAGCATCT 1050
AGACTCGGTCACGAAATTACCGTACAGTCTGTCTTGAACTTACACAGTCCACTGGGACTACTTTTGTATCGTAGA
CAGGAGATTTCATGCCTGGTGCTTCCAAATATTGTTGACAACTGTGACTGTACCCAAATGGAAAGTAACTCATTT 1125
GTCCTCTAAAGTACGGACCACGAAGGTTTATAACAACTGTTGACACTGACATGGGTTTACCTTTCATTGAGTAAA
GTTAAAATTATCAATATCTAATATATATG.LAA-TGTAAGTTC 1200
CAATTTTAATAGTTATAGATTATATATACTTATTTCACATTCAAG
Fig. 3 Nucleotide sequence of human IFN41 cONA
The nucleotide sequence was determined by the Maxam and Gilbert technique
(35). The initiation and termination codons are shown in full outlined
boxes. The AATAAA sequence near the polyadenylation signal is shown in a
dashed box. The coding region is indicated by a heavy line above the
nucleotide sequence; the vertical arrow indicates the position where the
presumed signal peptide is cleaved.
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3LYS-TYR-THR-SER-TYR- I LE-LEU-ALA-PHE-GLN-LEU-CYS-I LE-VAL-LEU-GLY-SER-LEU-GLY-
CYs-TYR-CYs-GLN-ASP-PRO-TYR-VAL-LYS-GLu-ALA-GLu-ASN-LEU-LYS-Lys-TYR-PHE-ASN-ALA-GLY-HI S-SER-ASP-VAL-
-Y + + -- -+ +
ALA-ASP-ASN-GLY-THR-LEU-PHE-LEU-GLY- I I-LEU-Lys-ASN-TRP-Lys-GLU-GLU-SER-ASP-ARG-LyS-I LE-MET-GLN-SER-
5
+ + +
_ _
+ 75
GLN-ILE-VAL-SER-PHE-TYR-PHE-LYS-LEU-PHE-LYS-ASN-PHE-LYS-ASP-ASP-GLN-SER-I LE-GLN-LYS-SER-VAL-GLU-THR-
I LE-LYS-GLU-AsP-MET-ASN-VAL-Lys-PHE-PHE-ASN-SER-ASN-Lys-Lys-Lys-ARG-Asp-AsP-PHE-GLu-Lys-LEu-THR-ASN-
-
~~~~++ - - 125TYR-SER-VAL-THR-ASP-LEU-ASN-VAL-GLN-ARG-LYS-ALA-I LE-HI s-GLU-LEu-I LE-GLN-VAL-MET-ALA-GLU-LEU-SER-PRO-
+ + + + + + + + 14ALA-ALA-LYs-THR-GLY-LYS-ARG-LYS-ARG-SER-GLN-MET-LEu-PHE-ARG-GLY-ARG-ARG-ALA-SER-GLN 146
Fig. 4 Amino acid sequence of human IFN-Y
The amino acid sequence consists of a presumed 20-amino acid signal
peptide, starting from the boxed methionine up to the vertical arrow,
plus a mature polypeptide. The underlined sequence Glu-Glu occurs in all
three forms of IFN at approximately the same position. Y indicates the
potential N-glycosylation sites; + and - indicate basic and acidic amino
acid residues respectively.
molecule exists as a complex of subunits, most probably as a dimer.
The amino acid sequence of IFN4 also reveals two potential
N-glycosylation sites at positions 28 and 100. Different degrees of
glycosylation at these sites could result in the formation of multiple
subspecies of denatured IFN-r polypeptides as observed by Yip et al. (23)
and by Chen et al. (45). The amino acid sequence shows a remarkably high
content of basic residues which would explain the high pI value observed
by Yip et al. (22). More particularly, there are two clusters of four
consecutive basic residues, viz. Lys-Lys-Lys-Arg (at position 89-92) and
Lys-Arg-Lys-Arg (at position 131-134). The basic nature of the mature
protein may be related to the acid lability of its biological activity.
Since the only cysteine residues in the amino acid sequence occur at the
NHI-terminal end (positions 1 and 3), it is unlikely that disulphide
bridges are essential for maintaining the conformation of the mature
protein. This is in agreement with the finding that the antiviral
activity is retained after treatment with/p-mercaptoethanol (22, 23, 45,
49) and with the observation that there is sulfhydryl specific binding of
human IFN4Y on an Affigel 501 matrix (50). The nucleotide sequence that
we have determined for the IFN4Y mRNA and the amino acid sequence deduced
for IFN-I are in agreement with the data recently obtained by Gray et al.
(29), except for the amino acid residue at position 140 which we
determined to be an arginine residue as opposed to a glutamine residue
(CGA codon versus CAA). The correctness of our nucleotide sequence was
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further demonstrated by the presence of two consecutive TaqI sites at
these positions (Fig. 2). It remains to be shown whether this could be
an example of allelic variation. The homology between the amino acid
sequences of IFN-Y and several recombinant forms of IFN-X was examined by
Epstein L.B. (51) who found that there are 18 identical amino acids or
very conservative replacements in precise sequence order. Moreover, the
sequence Glu-Glu occurs in all three forms of IFN at approximately the
same position (residues 41 and 42 in IFN-( and IFN-4, residues 42 and 43
in IFN-1S). The conservation of these two residues is remarkable in view
of the experimental finding that the receptor for IFN-T is different
from that of IFN-4L and IFN"/ (21) and that IFN exerts its action
without internalization (52, 53).
Transfection of AP8 monkey cells with pHIIF-SV-Y DNA
In order to prove that the clone that we had isolated did actually
code for human IFN4Y , it was necessary to express the genetic
information and to characterize the resulting product. From the results
obtained by restriction analysis, it was apparent that only clones
pHIIF-SV-l, pHIIF-SV-55 and pHIIF-SV-T10 contained the complete coding
region of human IFN-' . These clones were therefore the only candidates
for expression of IFN-4 in monkey cells transfected with these plasmids.
Furthermore, analysis based on locating the AvaII site (which is present
Table 2 IFN production by monkey cells (AP8) transfected with plasmid DNA
Plasmid DNA (a) (O.lJg/20 mm well) Laboratory units (b)
pHIIF-SV-yl 100
pHIIF-SV-}5 <3
pHIIF-SV-lf0 < 3
pSV529-HFIF-1 10,000
pHIIF-SV-gl C 3
pH2 treated (c)
a pHIIF-SV-Il contained the IFN-S information in the sense orientation
relative to SV40 late transcription; pHIIF-SV-65 and pHIIF-SV-+O0 containedthe information in an antisense orientation.
b One leucocyte I.U./ml equals 50 laboratory units/ml.
c For pH2 treatment the sample was dialysed overnight against 0.01M
glycine.HCl, pH 2.0 buffer, and followed by dialysis against phosphate
buffered saline.
Conditions for culturing the AP8 cells and transfection with plasmid DNA are
as described by Gheysen, D. and Fiers, W. (1).
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Table 3 Serological characterization of cloned pHIIF-SV-Xl interferon
IFN Laboratory units/ml
IFN-oC standard 30
id. + antioX-serum (S) 43
IFN-P standard 300id. + anti /-serum (G) (3
IFN-; standard 100
id. + antis -serum (R) <3
id. + anti x-serum (M) <3
IFN (AP8 cells + pHIIF-SV-p) 100id. + anticd-serum (S) 100
id. + anti (-serum (G) 160
id. + anti 6-serum (R) <3id. + anti s-serum (M) <3
Sera used: antioL (sheep - K. Cantell); anti (goat - E. De Clercq & A.
Billiau); anti b (rabbit - Langford & Stanton); antiX (mouse - this
laboratory).
at the 5'-end of the IFN-4 cDNA) showed that the cONA in the plasmids
pHIIF-SV-15 and pHIIF-SV-410 was inserted in an opposite orientation
relative to the SV40 late promoter. Since the expression of human IFN-A
in monkey cells transfected with the chimaeric plasmid-SV40 containing
IFN-,9 cDNA required the IFN-,2 cDNA insert to be correctly orientated (1),
pHIIF-SV-W1 was the only clone which could possibly lead to expression of
IFN-4 after transfection of cultured monkey cells. Table 2 shows that
pHIIF-SV-Wl was indeed the only clone that resulted in the appearance of
an antiviral activity after transfection of AP8 cells. This IFN activity
was neutralized by an anti-human IFN-16 serum but not by anti IFN-OC or
anti IFN-/ serum and is therefore immune IFN specific (Table 3). The
antiviral activity was acid labile (Table 2), and showed no virus
protection on bovine, murine or feline cells (not shown). However, the
antiviral activity of IFN-/3, produced after transfection of AP8 cells
under similar conditions with an IFN-f cONA containing plasmid
(pSV529-HFIF) was about 100 times higher. Clearly, this high level of
expression is necessary for detection of an IFN cDNA containing clone in
a mixture of randomly cloned cONA. The low level of expression of IFN-
in AP8 cells transfected with pHIIF-SV-1l DNA could explain our inability
to detect this clone using our direct screening method (see above). The
reason for the difference in expression level between IFN-' and IFN-f3
containing chimaeras is not clear at present and needs further study.
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